Plain-English translation of NCT02670408 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This research study is testing a new diagnostic system called the Molecular Microscope Diagnostic System (MMDx) that uses molecular testing to better identify rejection in heart transplant patients. Currently, doctors rely on older methods that sometimes give incorrect results, which can lead to wrong treatment decisions. This study will collect and analyze heart biopsy samples from 900 heart transplant patients to see if the new testing method is more accurate and helpful in real patient care.
After a heart transplant, doctors need to know whether the body is rejecting the new heart. The current standard method for diagnosing rejection sometimes misses problems or gives false alarms, leading to patients receiving treatments they may not need—or missing treatments they do need. This new molecular approach aims to give doctors a clearer, more accurate picture so they can make better treatment decisions.
You likely qualify if…
You likely don't qualify if…
If you qualify, your participation is straightforward: you will have a heart biopsy collected as part of your regular clinical care (this would likely happen anyway as part of your transplant monitoring). The research team will then use advanced molecular testing to analyze your biopsy sample alongside standard testing methods. You may be asked to allow your clinical information and biopsy results to be reviewed and used to help develop and refine the new diagnostic system. The study is currently enrolling patients at centers across North America and Europe.
AI-generated summary from trial data · Jun 22, 2026 · Not medical advice
United States